T ogether with a thorough history and physical examination, a simple 12-lead ECG is perhaps the most inexpensive and accessible cardiovascular assessment available. For the evaluation of coronary heart disease, the ECG is indispensable as a diagnostic, prognostic, and therapy-guiding tool in the evaluation of acute ischemic symptoms. For example, in a patient with ongoing angina, the presence of ST-segment elevation identifies a potential acute myocardial infarction (MI), categorizes a patient at high risk of death, and prompts a strategy of immediate reperfusion.
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In contrast, among stable, asymptomatic patients, the role of a screening ECG to detect prior MI is less clear. A screening test is only as good as its diagnostic performance (sensitivity and specificity), the prevalence of the disease in the population, and the clinician's pretest suspicion or probability that the patient has the disease. Thus, what testing criteria we use, in which population we use it, and how we approach the actual patient can dramatically alter the utility of a test like the ECG for detecting ischemic heart disease.
Pathological Q waves are the most well-accepted marker of myocardial damage on a surface ECG and, when discovered incidentally, are often called silent, or unrecognized, MI. 1, 2 Since the Framingham Study reported >40 years ago that silent MIs accounted for almost one quarter of all MIs during 20 years of follow up and carry a poor prognosis similar to that of symptomatic MI, 3 the prevalence and prognostic implications of Q waves have been evaluated in many cohort and clinical settings. 4, 5 The data supporting universal ECG screening, however, remain inconclusive, and the US Preventive Services Task Force recommends against the use of screening ECGs in the general population, in which the overall prevalence of ischemic heart disease is low. 6 The question remains about what to do in higher-risk populations. In patients with documented ischemic heart disease, the 2012 American Heart Association/American College of Cardiology "Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease" states that "a resting 12-lead ECG at 1-year or longer intervals between studies in patients with stable symptoms might be reasonable." The guideline acknowledges the lack of data to support this expert consensus (Level of Evidence: C) and gives it only a Class IIb recommendation. 7 Patients with diabetes mellitus constitute another important population at high risk for cardiovascular disease in whom, logic would follow, screening ECGs could be useful. Overall, the prevalence of unrecognized or silent MI appears to be higher in patients with diabetes mellitus compared with nondiabetics, ranging from 2% to 7%; however, the prevalence depends largely on the age and comorbidities of the population studied [8] [9] [10] (Table 1 ). Several studies in diabetic patients assessed serial ECGs over several years and found overall a low incidence of silent MI detected by Q waves, although they accounted for up to one third of all MIs identified (symptomatic and asymptomatic; Table 2 ). 10, [12] [13] [14] [15] The studies are discordant on the question of whether a silent MI is associated with a significantly increased risk of future cardiovascular events.
To this literature, the report by Davis et al, 11 on behalf of the UK Prospective Diabetes Study (UKPDS), adds new and clinically relevant information. Between 1977 and 1991, the UKPDS enrolled 5102 newly diagnosed diabetic patients without overt cardiovascular disease and found that more intensive glucose control significantly reduced the risk of microvascular complications and, after 20 years of follow-up, MI and overall mortality. In the present analysis, clinical follow-up is extended to an impressive 30 years. Core laboratory review identified pathological Q waves in a surprisingly high proportion of subjects at baseline (17.5%) and at 12 years (30.1%). The high prevalence of silent MI raises the concern that the ECG criteria used in this study were not specific enough to exclude non-infarct-related ECG abnormalities.
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Despite the inclusion of potential false-positive MI events and in contrast to most of the studies in lower-risk diabetic populations, the presence of Q waves on baseline ECG was associated with a >50% increased risk for subsequent MI and a 30% risk for all-cause mortality, even after robust adjustment for baseline risk factors. The length and completeness of follow-up certainly were key to the full evaluation of the longterm cardiovascular risk associated with ECG abnormalities.
Simply demonstrating an independent association between a clinical biomarker like Q waves and outcomes, however, is not sufficient to support its incorporation into clinical practice. 16 And to their credit, the authors evaluated the incremental prognostic utility of the screening ECG by calculating changes in statistical metrics of discrimination such as c statistics, integrated discrimination index, and net reclassification. 17 Despite the robust association between Q waves and outcomes with traditional proportional hazard models, the addition of Q waves to the UKPDS risk engine failed to meaningfully change either the c statistic or net reclassification. The change in integrated discrimination index was small and without any likely clinical relevance. Thus, identification of Q wave does not improve risk stratification beyond a clinical model alone.
How then do we interpret the data in the context of prior studies? Overall, the UKPDS was a relatively low-risk population, free of symptomatic cardiovascular disease. The absence of any incremental improvement in risk stratification is therefore consistent with the recommendations against screening ECGs for primary prevention. 6, 18 Another key question about any clinical test is whether the results would alter therapy. In UKPDS, there was no interaction between Q waves and randomization to a more intensive glucose regimen. In other words, the presence of a Q wave on baseline ECG did not identify patients who would benefit from more aggressive glycemic management. This is discouraging but also consistent with the results of the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study, which randomized 1123 patients with diabetes mellitus but no history or symptoms of coronary disease to screening myocardial perfusion imaging or no screening. Detection of an imaging abnormality identified patients at increased risk of death; however, the overall strategy of universal screening failed to demonstrate any reduction in the clinical risk. 19 Why does screening with an ECG not work in patients with diabetes mellitus? First, the ECG is an imperfect test for the detection of MI. Consistent with other studies, a high proportion of baseline Q waves identified in the UKPDS disappeared after 3 years. Given the low prevalence of vascular disease in UKPDS, most of the transient Q waves were likely false positives and not, in fact, true infarcts. Q waves also lack sensitivity because, in many cases, they recede months or years after a true infarct. In addition, a significant number of infarcts never evolve into Q waves because of either infarct location or the degree of myocardial damage. 20 What then are the implications for the utility of the ECG to detect silent MI? In clinical research, screening and serial ECGs may be useful in identifying potential unrecognized MI because they will increase the overall event rate by 10% to 25% and because they may be modifiable end points in a randomized trial. However, any newly identified Q wave requires further confirmation with a follow-up ECG and a formal adjudication that reviews the entire clinical history. Many silent MIs are actually unrecognized and become apparent only when the clinical history is carefully reviewed.
For clinical care, the evidence and guidelines do not support the routine use of screening ECGs to detect new Q waves in patients with diabetes mellitus. Regardless of the presence of prior MI, cardiovascular risk factors in patients with diabetes mellitus should be aggressively controlled, and in high-risk patients, antiplatelet therapy is indicated. 18, 21 These are the therapies that improve outcomes. If new Q waves are identified during routine clinical care, cardiac imaging should be performed to identify the presence and extent of actual myocardial damage before a "silent" MI is diagnosed.
After 100 years, the role of the ECG continues to evolve. Studies like this one by Davis et al, with well-characterized populations, long follow-up, and rigorous statistical modeling, are needed to further define the optimal clinical indications for ECG testing. 
